Other antianginal drugs (Formulary)

Refer to the Stable angina management guideline.

IVABRADINE

Important: Therapy notes

MHRA advice: Ivabradine: carefully monitor for bradycardia (December 2014) (www.gov.uk)
MHRA advice: Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects (December 2014) (www.gov.uk)

Important: Formulation and dosage details

Formulation:

Tablets 5mg, 7·5mg

Dosage:

Angina: (for people in sinus rhythm) initially 5mg twice daily, increased if necessary after 3 to 4 weeks to 7·5mg twice daily (if not tolerated reduce dose to 2·5 to 5mg twice daily); older people initially 2·5mg twice daily.
Chronic heart failure NYHA II to IV with systolic dysfunction, in patients in sinus rhythm whose resting heart rate remains at 75 or more beats per minute despite optimal standard therapy: (specialist use only) initially 5mg twice daily, increased if necessary after 2 weeks to 7·5mg twice daily (if not tolerated reduce dose to 2·5mg twice daily). Ventricular rate at rest should not be allowed to fall below 50 beats per minute.

NICORANDIL

Important: Therapy notes

MHRA advice: Nicorandil (Ikorel): now second-line treatment for angina - risk of ulcer complications (January 2016) (www.gov.uk)
MHRA advice: Nicorandil: risk of gastrointestinal ulceration (December 2014) (www.gov.uk)

Important: Formulation and dosage details

Formulation:

Tablets 10mg, 20mg

Dosage:

Initially 10mg twice daily (if susceptible to headache, 5mg twice daily), usual dose 10 to 20mg twice daily; up to 30mg twice daily may be used.

Editorial Information

Document Id: F057